Religare Enterprises Gears Up for Demerger, Burman Group Infuses ₹750 Cr

Care Health's Assets Under Management (AUM) have surpassed INR 10,000 crores, and the Burman Group has committed INR 750 crores through a preferential rights issue.
Reader Takeaway: Health insurance growth is strong; housing finance turnaround and legal recoveries remain key watchpoints.

What just happened (today’s filing)

Religare Enterprises Limited (REL) outlined its demerger strategy and segment performance during its FY26 concall. The company aims to create two focused, listed entities: Religare Finvest (RFL) for lending and broking, and Religare Enterprises (REL) as a pure-play health insurance holding company.

The Burman Group, now the promoter, has committed INR 750 crore via a preferential rights issue, increasing its stake to 30.3%. This capital infusion supports the company's strategic realignment and growth initiatives across its subsidiaries.

Why this matters

This structural change promises greater operational focus and clarity for investors. Separating the high-growth health insurance business from the lending arms allows each entity to pursue its specific growth trajectories and attract tailored capital.

The backing of the Burman Group provides significant financial stability and strategic direction, especially as the company navigates the demerger process and aims for profitability across all segments.

The backstory (grounded)

The Burman family's increasing stake and promoter status follow a period where Religare Finvest (RFL) faced significant challenges, including past allegations of fraud and financial distress under previous management. The current leadership is focused on rebuilding RFL as a debt-free entity with strong capital adequacy.

What changes now

• Shareholders can anticipate two distinct listed investment opportunities: one focused on health insurance growth and the other on a stabilized lending and broking business.
• Management emphasis will shift to driving specific growth and profitability targets within each demerged entity.
• The company aims to reduce its holding company discount by creating clearer value propositions for each business segment.
• The debt-free status of Religare Finvest is a key outcome of past restructuring efforts, providing a clean balance sheet for future operations.

Risks to watch

• A mark-to-market loss of INR 64 crore on equity investments was reported for the fiscal year, reflecting market volatility.
• The housing finance division continues to operate at a loss, posting INR 18.6 crore for FY26, with a projected turnaround timeline of 12-18 months.
• Legal proceedings are ongoing in the Delhi High Court to recover funds related to a fraudulent fixed deposit allegedly taken from RFL by Lakshmi Vilas Bank (LVB).

Peer comparison

Care Health Insurance is positioned within India's expanding health insurance market, alongside peers like Star Health and Allied Insurance, which reported Gross Written Premium of INR 13,414 crore for FY23.

Religare Finvest operates in the NBFC lending space, where peers like Cholamandalam Investment and Finance Company have substantial AUM, reporting INR 96,250 crore as of March 31, 2023. Religare Finvest, however, is noted for its debt-free status and high CRAR.

Context metrics (time-bound)

• Care Health's retail health segment grew by 34% annually.
• Religare Finvest reported a CRAR of 261% as of the reported period.
• Religare Broking reported INR 22 crores PAT despite a 2% annual top-line decline.

What to track next

• Progress and timelines for the formal demerger process and regulatory approvals.
• Performance of the housing finance business towards its targeted profitability.
• Resolution of the Lakshmi Vilas Bank fraudulent FD case and potential recovery.
• Execution of Care Health's guidance for 18-24% growth and a combined ratio near 100%.
• Potential strategic investor activities or stake changes post-demerger.